March 04, 2022
Drug payors pressed a New Jersey federal judge Thursday not to let Celgene Corp. and parent Bristol-Myers Squibb Co. "delay justice and perpetuate the illegal conduct" preventing generic competition for two blockbuster cancer drugs, arguing that the drugmakers cannot use separate, "significantly different" litigation to justify a pause.
February 22, 2022
Two nonprofits have been added to a sweeping antitrust lawsuit accusing Celgene Corp. and parent Bristol-Myers Squibb Co. of stifling generic competition for two blockbuster cancer drugs and driving up prices for secondary payers of health care claims.